State Medicaid audit exposes PBM billing tactics that hide true drug costs from payers

A state audit of Medicaid records found that pharmacy benefit managers are using complex claims-processing methods that obscure actual drug costs and result in taxpayer overcharges. The findings add to a growing body of evidence that PBM contracting structures lack the transparency needed for meaningful oversight.

Why it matters

A state audit of Medicaid prescription drug records found that pharmacy benefit managers are using layered claims-processing tactics that make it difficult to determine what was actually paid for a drug versus what was billed to the state. The result, according to the audit, is systematic overcharging of taxpayers. This is not a new allegation, but a state audit with documented methodology carries more weight than advocacy-driven estimates.

For health system and pharmacy leaders, the practical implication is straightforward: if state Medicaid programs with audit authority cannot easily reconcile drug costs, the information asymmetry in commercial and employer PBM contracts is likely at least as severe. The policy conversation is shifting toward structural disclosure requirements rather than voluntary transparency pledges, and that shift will eventually reach every payer category. Leaders who wait for federal action before auditing their own PBM relationships are accepting risk they do not have to accept.

What to watch

Whether this audit triggers legislative action on PBM spread pricing disclosure requirements or referrals to federal oversight bodies like CMS or the FTC.